Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- Editor’s Pick: Five Healthcare News Headlines for July 21 - August 9
August 10, 2015
- MHLW Notifies of Package Insert Changes for Daklinza, Sunvepra
August 10, 2015
- “Greater Emphasis” Will Need to Be Placed on R&D in Field of Oncology: AMED President
August 7, 2015
- MHLW Calls for Package Insert Revision for Inavir, Relenza
August 7, 2015
- Health Minister Reviewing Ways to Strengthen Guidance to Optimize Ethical Drug Ads: Senior Vice Minister Nagaoka
August 6, 2015
- PAFSC 2nd Committee Endorses Approval of AZ’s Vandetanib
August 5, 2015
- Lupus Nephritis to Be Added to Cellcept’s Indication: MHLW Notification
August 4, 2015
- PAFSC’s First Committee Supports Approval of Actelion’s Tracleer for Digital Ulcers in Generalized Scleroderma
August 3, 2015
- AMED Sets Up 5-Step Process to Pick Licensees of Academic Drug Seeds
July 30, 2015
- MHLW to Continue Discussions on Elderly Use of Prevenar 13 under National Vaccination Program
July 29, 2015
- Finance Minister Calls for Revision of Special Measures on Taxation “Without Preconceptions”
July 28, 2015
- Government Approves Basic Policy on Budget Requests for FY2016
July 28, 2015
- ICH Assembly to Make Final Decisions on All Important Issues: PMDA Official
July 27, 2015
- Japan Embarking on Biosimilar Development, but It’s a Race against Time: MHLW Official
July 24, 2015
- Japan Eyes Linking Dormant Pricing Premium with Sakigake System, Upping Rate to 20% at Maximum
July 24, 2015
- Chuikyo Subcommittee OKs Plan to Draft GL for Analyzing Cost-Effectiveness; QALY Expected to Be Main Index
July 24, 2015
- Drug Pricing Organization Proposes Re-Pricing of Products with Huge Sales
July 23, 2015
- Kaketsuken Withdraws Earlier Explanation of Blood Products Scandal; Problem Discovered through Information Provided to MHLW
July 23, 2015
- AMED Takes Initial Step Toward Out-Licensing First Lead Compound; Now Taking Applications from Companies
July 23, 2015
- PMDA Calls for Caution for Use of Inavir, Relenza in Patients Allergic to Milk Products
July 23, 2015
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…